GRONINGEN, Netherlands, Feb. 11 /PRNewswire/ -- Polyganics B.V. has
announced that the first patients have been enrolled in the multi-center
clinical study for its degradable nasal dressing. The study is conducted by
Dr. Hans Claessen (Groningen), Dr. Tjasse Bruintjes (Apeldoorn) and Dr.
Maarten Majoor (Ede), all in The Netherlands. The clinical study objective is
to assess intra nasal healing after application of the degradable nasal
dressing at 10 and 30 days post procedure.
Commercially available non-degradable nasal dressings need to be removed
after several days, which is associated with strong discomfort for the
patient. The Polyganics' degradable nasal dressing exhibits compressional
strength comparable to the currently available non-degradable dressings but
offers highly enhanced comfort to the patient as it degrades over time. After
degradation, the dressing is drained from the nasal cavity. Therefore no
additional removal procedure is required anymore, which avoids a painful
follow-up visit for the patient.
The Polyganics' nasal dressing is composed of a purely synthetic material
offering maximum safety and comfort to the patient as an alternative to
currently used non-degradable or animal-derived materials. The Polyganics'
nasal dressing can be applied as a post-surgery nasal dressing but also to
treat severe nose bleedings.
If the trial is successful, Polyganics has the first commercially
available nasal dressing combining strength and patient comfort, says Jan Smit
(Managing Director). The global market for nasal dressings has an estimated
potential of $150 million per year.
The degradable nasal dressing is one of a series of medical products based
on Polyganics' proprietary synthetic bioresorbable materials that exhibit
superior properties and offer break-through new alternatives for e.g.
animal-derived materials. The Polyganics' nasal dressing is expected to
receive FDA clearance and CE Mark registration in 2003.
Polyganics B.V., a privately held biomedical company based in The
Netherlands, develops and manufactures medical devices based on bioresorbable
biomaterials, including biodegradable surgical implants, injectable/implant
drug delivery systems and bioactive coatings. Polyganics designs synthetic
biomaterials and new product concepts that will be sold globally through
strategic alliances and distributors.
Polyganics' novel synthetic bioresorbable products strongly reduce the
number of medical interventions, thereby improving patient compliance and
comfort while reducing health care costs. Polyganics B.V. has its
headquarters, manufacturing and research facilities in Groningen, The
Netherlands. Please visit the Company's website at http://www.polyganics.com,
SOURCE Polyganics B.V.